Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.

CNS Drugs · 2021 · PMC8219567 · PMID 34003459

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the fourth phase III trial (adolescents, N = 292), the primary efficacy endpoint (improvement on ADHD-Rating Scale, Fifth Edition total scores) did not reach statistical significance for once-daily viloxazine ER 600 mg, despite being statistically significant for patients treated with the 400-mg dose [ 39 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.